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Background: Neoadjuvant chemoradiotherapy (nCRT) combined with surgery has been implemented as a standard
treatment strategy in locally advanced rectal cancer (LARC). However, there is a wide spectrum of response to
nCRT. The aim of this study was to determine whether enhancer of zeste homologue 2 (EZH2 ) expression could
predict response to nCRT and outcomes for patients in LARC.
Method: The study examined the EZH2 expression in 112 biopsies by immohistochemistry. The associations
between EZH2 and clinical characters were analyzed.
Results: EZH2 expression in biopsy tissue was significantly related to increased tumor cell proliferation, as assessed
by Ki-67 expression with a cutoff value of 37% (p <0.001). High EZH2 expression was correlated closely with low
differentiation (p = 0.029), high CEA level (p = 0.041), T4 status (p = 0.011) and node metastasis (p =0.045). By univariate
and multivariate analysis, we observed low EZH2 expression could reliably and independently predict the good
response to nCRT ( p = 0.026 and p = 0.023) and down-staging ( p = 0.021 and p = 0.027). In univariate analysis,
high EZH2 expression was significantly associated with poor 5-year disease-free survival (p = 0.025) and 5-year
overall survival (p = 0.032). In multivariate analysis, EZH2 was a prognostic factor for 5-year DFS (HR = 2.287; 95%
CI 1.137-4.602, p = 0.020) but not for 5-year OS (HR = 2.182; 95% CI 0.940-5.364, p = 0.069).
Conclusion: Our study revealed that low EZH2 expression in biopsy tissue might be a useful predictive factor of
good tumor response to nCRT and longer 5-year DFS in patients with LARC. However this is a relatively small
retrospective study, to further validate the role of EZH2 in rectal cancer, large consistent cohort studies are
needed.
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Rectal cancer is one of the leading causes of cancer-
related mortality and morbidity in the world [1]. Over the
last two decades, advances in new treatment strategies
have contributed significantly to the improvement of local
recurrence and overall survival rate in patients with locally
advanced rectal cancer (LARC) [2,3]. Evidences from
randomized clinical trials strongly support the treatment
of rectal cancer with neoadjuvant chemoradiotherapy* Correspondence: sdyujinming@126.com
1Department of Radiation Oncology of Shandong Cancer Hospital and
Institute, No. 440 Jiyan Road, Jinan, Shandong 250117, China
Full list of author information is available at the end of the article
© 2014 Meng et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.(nCRT) and surgery [4,5]. Due to the heterogeneous re-
sponses to nCRT, identifying a predictive or prognostic
molecular marker is important to discriminate those pa-
tients who would benefit from nCRT and avoid unneces-
sary treatment with toxic side effects.
Enhancer of zeste homologue 2 (EZH2), as a member
of the polycomb group of genes has important functions
in tumor aggressiveness [6]. Its amplification was first
studied in hematologic malignancies [7]. Disruption of
EZH2 expression was observed to correlate closely with
tumor aggressiveness and/or poor patient prognosis in
prostate [8], oral [9], bladder [10], esophageal [11],
breast [12] and ovarian cancers [13]. EZH2 is a cell cycletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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maturation and differentiation [14]. Over-expression of
EZH2 was also observed to shorten the G1 phase of the
cell cycle and lead to accumulation of cells in the S phase
[15], which might play a critical role in radioresistance
[11,16]. Furthermore, as an essential downstream target of
pRB/E2F pathway, EZH2 is a critical mediator of E2F
function [15]. E2F1 has been observed to be associated
with radiosensitivity and/or chemosensitivity in certain
types of tumors [17-19]. In esophageal squamous cell car-
cinoma (ESCC), high EZH2 expression was significantly
correlated with lack of clinical complete response to CRT
(p = 0.028) and poor disease-specific survival (p < 0.001)
[11]. In atypical teratoid/rhabdoid tumor (ATRT), targeted
disruption of EZH2 by RNAi or pharmacologic inhibition
strongly impaired cell growth, suppressed cell self-renewal,
induced apoptosis, and potently sensitized these cells to ra-
diation [16].
However, there is limited study concentrating on the
predicting role of EZH2 in LARC. In the present study
we examined the expression of EZH2 protein in pre-
treatment biopsies by immunohistochemistry (IHC), so
as to determine whether EZH2 expression has predictive
value of nCRT response and prognosis in patients with
LARC.Materials and methods
Patients and clinical assessment
The clinicopathological characteristics were reviewed
retrospectively for the purpose of the study. All patients
were diagnosed with primary rectal adenocarcinoma con-
firmed by rigid rectoscopy. Before treatment, tumor-node-
metastasis (TNM) stage was determined by a series of exam-
ination including physical examination, carcinoembryonic
antigen (CEA) serum level, chest computed tomography
(CT), contrast-enhanced CT and/or magnetic resonance
imaging (MRI) of the abdomen and pelvis. TNM stages
were reported according to the American Joint Commit-
tee on Cancer (AJCC) [20]. Informed consents were ob-
tained from all patients and the research protocols were
approved by the Ethics Committee of Shandong Cancer
Hospital and Institute.Multimodal treatment
112 patients received concurrent chemotherapy and
radiotherapy followed by surgery. In brief, patients
underwent whole pelvis preoperative radiotherapy with
a dose of 50.4 Gy in 28 fractions using three-dimensional
conformal irradiation or four-field box technique. Concur-
rent chemotherapy regimens include continuous infusion
of 5-fluorouracil ± oxaliplatin or capecitabine ± oxaliplatin.
Four to six weeks after the completion of nCRT, total
mesorectal excision (TME) was performed.Pathologic assessment
Histopathologic examination was performed by two pathol-
ogists who were blinded for all clinical data. Pathologic
TNM staging was performed on the surgical specimens to
assess for tumor down-staging according to the current
classification [20].
Tumor response was also evaluated using the tumor re-
gression grade (TRG) system proposed by Dworak et al.
[21]. Details as follows: grade 0, no regression; grade 1,
minor regression; grade 2, moderate regression; grade 3,
good regression; and grade 4, total regression, no viable
tumor cells. In the present study, TRG 3 and 4 were de-
fined as “good response” while TRG 0–2 were defined as
“poor response.”
Immunohistochemistry
Tumor samples were collected from pretreatment tumor
biopsies in 112 patients who received nCRT. The EZH2
and Ki-67 status was assessed using paraffin-embedded
tissue samples that were cut into 5 μm slices. The process
of staining was performed according to the product proto-
col. Briefly, all sections were deparaffinized in xylene and
rehydrated with distilled water through a graded series of
ethanol solutions. Antigen retrieval was performed under
high pressure for 2 minutes. Nonspecific binding was
blocked by the application of serum at 37°C for 15 minutes
(Beijing Zhongshan Golden Bridge Biotechnology Com-
pany, Beijing, China). For EZH2, the sections were stained
with primary monoclonal rabbit anti-human EZH2 anti-
body ( Abcam, Cambridge, UK) in humidified chamber at
37°C for 60 minutes, with a diluted ratio of 1:200. Second-
ary goat anti-rabbit antibody was incubated at 37°C for
30 minutes (Beijing Zhongshan Golden Bridge Biotech-
nology Company, Beijing, China). For Ki-67, the sections
were stained with primary monoclonal mouse anti-human
Ki-67 antibody (Beijing Zhongshan Golden Bridge Bio-
technology Company, China) in humidified chamber at
37°C for 60 minutes, with a diluted ratio of 1:100. Second-
ary goat anti-mouse antibody was incubated at 37°C for
30 minutes. Both EZH2 and Ki-67 expression were visual-
ized using 3,3’-diaminobenzidine (DAB) and subsequently
counterstained with hematoxylin.
Two independent observers who were blinded to the
clinicopathologic parameters performed scoring using a
previously validated scoring system for EZH2 expression
[10,11,22,23]. This system scores nuclear EZH2 expres-
sion by recording the percentage of positive nuclei stain-
ing for the EZH2 protein, irrespective of staining
intensity. EZH2 staining was classified into 2 groups:
high expression, when at least 50% of the cells showed
positive immunoreactivity in the nuclei and low expres-
sion, when positive cells were less than 50%. For Ki-67
immunohistochemistry, the percentage of positive nuclei
staining tumor cells was assessed in five representative






EZH 2 expression p
Low High value
Gender
Male 71 32 39 0.530
Female 41 21 20
Age(years)
<62 49 26 23 0.283
≥62 63 27 36
Histology
Differentiated 64 36 28 0.029
Undifferentiated 48 17 31
CEA(ng/ml)
<3.4 52 30 22 0.041
≥3.4 60 23 37
Distance from anal verge (cm)
<6 39 20 19 0.539
≥6 73 33 40
Clinical Tumor status
cT3 62 36 26 0.011
cT4 50 17 33
Clinical Node status
cN0 38 23 15 0.045
cN+ 74 30 44
Ki-67
Low 56 42 14 <0.001
High 56 11 45
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value, dividing the samples in low or high nuclear Ki-67
expression.
Follow-Up
Patients underwent a standardized post-treatment follow-
up including physical examinations, CEA serum level, per-
ipheral blood cell count, chest X-ray, every 3 months for
the first 2 years and every 6 months thereafter. Patients
also underwent abdominal and pelvic CT or MRI every
6 months. Colonoscopy was performed within 1 year after
treatment and then once every 2–3 years. The median
follow-up was 56 months.
Statistical analysis
For all the statistical analysis, Statistical Product and Ser-
vice Solutions (SPSS17.0) was used. The chi-squared test
was also performed to assess the association between
pathologic factors including EZH2 expression and tumor
response. A multivariate stepwise logistic regression ana-
lysis was performed in order to determine the independ-
ent prediction of all variables that were significant in the
univariate analysis. The associations between EZH2 pro-
tein expression and Ki-67 was also analyzed by Chi-square
test. For survival analysis, overall survival (OS) was de-
fined as the time from diagnosis to death from any causes
and was censored at the date of last contact for surviving
patients. Disease free survival (DFS) was defined as the
time from diagnosis to any evidence of local or systemic
cancer recurrence. The impact of the EZH2 status on
OS and DFS was determined using Kaplan-Meier method
for the univariate survival analysis and Cox proportional
hazards model for the multivariate survival analysis.




The clinicopathological parameters of the 112 patients
was detailed in Table 1. There were 62 cases assessed as
clinical T3 (cT3) while 50 cases as clinical T4 (cT4) and
38 patients assessed as clinical N0 (cN0) while 74 patients
assessed as cN+. There were 52 cases with CEA < 3.4 ng/
ml and 60 cases with CEA ≥ 3.4 ng/ml. With respect of
tumor localization, 39 tumors were localized in <6 cm and
73 localized in >6 cm from the anal verge. There were 44
cases assessed as pathological T1-2 (pT1-2) while 68 cases
as pathological T3-4 (pT3-4) and 67 patients assessed as
stage pathological N0 (pN0) while 45 patients assessed as
pathological N + (pN+). A comparison of pretreatment
staging results and histopathologic diagnosis after surgery
revealed AJCC down-staging in 52.7% patients (n = 59).
Tumor regression grade analysis showed good response
(TRG 3 and TRG4) in 47.3% patients (n = 53).Expression of EZH2 in LARC
In this study, protein expression of EZH2 was examined
by IHC(Figure 1). High expression of EZH2 was ob-
served in 59/112 (52.7%) biopsy specimens from patients
underwent nCRT. The median Ki-67 expression is 37%.
The association between clinicopathological parameters
and EZH2 expression levels were summarized in Table 1.
EZH2 expression was significantly related to increased
tumor cell proliferation, as assessed by Ki-67 expression
with a cutoff value of 37% (p <0.001).High EZH2 ex-
pression was correlated closely with low differentiation
(p = 0.029), high CEA level (p= 0.041), T4 status (p = 0.011)
and Node metastasis (p =0.045).
Correlation between EZH2 expression and CRT response
To determine the ability of clinicopathological parame-
ters to predict good histopathologic tumor response and
down-staging to nCRT, the chi-square test was used
(Table 2). It seemed that EZH2 low expression could
predict the response to nCRT: 30 cases in 53 EZH2 low
Figure 1 Immunohistochemical staining for EZH2 and Ki-67 in rectal cancer cell nucleus. A. Low expression of EZH2 (400×). B. Low
expression of Ki-67 (400×). C. High expression of EZH2 (400×). D. High expression of Ki-67 (400×).
Table 2 Correlations between clinicopathological parameters and tumor response
Parameters Cases
N = 112
Tumor regression grade p value Tumor p value
Good response Poor response Down-staging Non-down-staging
Age
<62 49 24 25 0.519 26 23 0.943
≥62 63 27 36 33 30
Sex
Male 71 34 37 0.511 41 30 0.157
Female 41 17 24 18 23
Distance from anal verge (cm)
<6 39 18 21 0.924 23 16 0.329
≥6 73 33 40 36 37
Histology
Differentiated 64 28 36 0.661 31 33 0.299
Undifferentiated 48 23 25 28 20
CEA(ng/ml)
<3.4 52 30 22 0.016 33 19 0.033
≥3.4 60 21 39 26 34
Clinical Tumor status
cT3 62 35 27 0.01 37 25 0.099
cT4 50 16 34 22 28
Clinical Node status
cN0 38 23 15 0.022 25 13 0.046
cN+ 74 28 46 34 40
EZH2
Low 53 30 23 0.026 34 19 0.021
High 59 21 38 25 34
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Male 71 62.8 0.631 76.7 0.354
Female 41 64.4 67.4
Age
<62 49 64.2 0.615 69.9 0.476
≥62 63 62.7 76.4
Distance from
anal verge (cm)
<6 39 59.9 0.375 68.4 0.286
≥6 73 66.1 76.7
Histology
Differentiated 64 68.0 0.267 78.2 0.139
Undifferentiated 48 56.3 66.5
CEA (ng/ml)
<3.4 52 68.2 0.320 77.0 0.380
≥3.4 60 58.9 66.7
Clinical Tumor status
cT3 62 70.0 0.046 81.4 0.021
cT4 50 54.2 59.4
Pathological Tumor status
pT0-2 44 73.3 0.034 83.4 0.019
pT3-4 68 56.8 65.3
Clinical Node status
cN0 38 78.6 0.011 84.0 0.008
cN+ 74 51.9 59.5
Pathological Node status
pN0 67 69.4 0.016 79.9 0.024
pN+ 45 54.5 61.7
EZH 2
High 53 74.0 0.025 82.8 0.032
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21 cases in 59 EZH2 high expression patients did (p =
0.026); 34 cases in 53 EZH2 low expression patients
achieved down-staging while 25 cases in 59 high expres-
sion patients did (p = 0.021). Low CEA level and non
node metastasis also showed significant correlation with
good tumor regression (p = 0.016 and p = 0.022) and
down-staging (p = 0.033 and p = 0.046). Tumors with
cT3 were more likely to achieve good response than
those with cT4 (p = 0.01).
By multivariate stepwise logistic regression analysis, we
found low expression of EZH2 showed significant correl-
ation with good tumor regression (OR = 2.684; 95% CI
1.147-6.280, p = 0.023) and down staging (OR = 2.476;
95% CI 1.107-5.537, p = 0.027). Moreover, cN was also
kept in the model as a predictive factor for good tumor re-
sponse (p = 0.018) and down-staging (p = 0.025) (Table 3).
Association of EZH 2 expression with Survival
EZH2 status, cN, cT, pathological tumor status (pT) and
pathological node status (pN) ,were found to be signifi-
cantly correlated with 5-year DFS and OS in univariate
analysis. As listed in Table 4, among 112 patients who
underwent nCRT, the 5-year DFS of 59 patients with EZH2
high expression was significantly poorer than that of 53 pa-
tients with EZH2 low expression (p = 0.025) (Figure 2A). In
the total study population, EZH2 high expression patients
had significant poorer 5-year OS as compared with EZH2
low expression patients (p = 0.032) (Figure 2B). In
multivariate analysis, we found the pN was an important
prognostic factor both for two end points while the pT
was only the prognostic factor of 5-year DFS (Table 5).
EZH2 was a prognostic factor for 5-year DFS (HR = 2.287;
95% CI 1.137-4.602, p = 0.020) but not for 5-year OS
(HR = 2.182; 95% CI 0.940-5.364, p = 0.069) (Table 5).
Discussion
In this study, we first examined the expression of EZH2
in LARC and its predicting significance in 112 patientsTable 3 Multivariate analysis for tumor response
Parameters Odds ratio 95% confidence interval P value
Good response
CEA 1.940 0.822-4.581 0.130
cT 2.580 1.080-6.161 0.033
cN 2.869 1.199-6.864 0.018
EZH2 2.684 1.147-6.280 0.023
Down-staging
CEA 1.624 0.735-3.589 0.231
cN 2.915 1.239-6.860 0.025
EZH2 2.476 1.107-5.537 0.027
EZH2: Enhancer of zeste homologue 2; CEA: carcinoembryonic antigen.
Low 59 53.8 64.1
DFS: Disease free survival; OS:overall survival.treated with nCRT. Our results showed that the high ex-
pression of EZH2 correlated with undifferentiation, high
CEA level, T4 status and lymph node metastasis status
at diagnosis. By univariate and multivariate analysis, we
observed low expression of EZH2 showed significant
correlation with good tumor regression (p = 0.026) and
down-staging (p = 0.021), which means EZH2 can reli-
ably and independently predict the response to nCRT
with LARC.
The results from the current study are in accordance
with the previous studies in other solid cancers [11,17].
In esophageal squamous cell carcinoma (ESCC), high
Figure 2 Kaplan-Meier estimates of disease-free survival(DFS) and overall survival (OS) rates in relation to EZH2 expression. A. The
5-year DFS was significantly shorter in patients with high expression patients than in patients with low expression(p = 0.025). B. The 5-year OS
was significantly shorter in patients with high expression patients than in patients with low expression (p = 0.032).
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creased cell proliferation (p = 0.009) and lack of clinical
complete response to CRT (p = 0.028) [11]. Pharmaco-
logic inhibition of EZH2 suppressed cell growth and in-
creased radiation sensitivity of ATRT cells [16]. In lung
cancer, EZH2 silencing with RNA interference (RNAi)
enhances A549 and HTB-56 cell sensitivity to irradiation
both in vitro and in vivo [23].
The sensitivity of chemotherapy and/or radiotherapy is
a complex phenomenon and regulated by a series of in-
ternal and extrinsic factors, including cell cycle arrest,
cell apoptosis, and DNA damage repair [24]. There are
two mechanisms possibly associated with resistance to
CRT of high EZH2 expression. First, EZH2 is a cell cycle
regulator [14]. A cDNA microarray study demonstrated
that disruption of EZH2 expression can retard cell pro-
liferation [25]. It is a fact that cells are not equally sensi-
tive to radiation throughout the cell cycle but showTable 5 Multivariate analysis for survival
Parameters Hazard ratio 95% confidence interval P value
5-year-DFS
EZH2 2.287 1.137-4.602 0.020
pT 2.244 1.076-4.678 0.013
pN 2.532 1.292-4.961 0.007
5-year-OS
EZH2 2.182 0.940-5.064 0.069
pT 2.395 0.997-5.365 0.051
pN 2.471 1.138-5.364 0.022increased radiation sensitivity in G2/M phase and de-
creased radiation sensitivity in S phase. Over-expression
of EZH2 was observed to shorten the G1 phase of the
cell cycle and lead to accumulation of cells in the S
phase [15]. Inhibition of EZH2 by interfering RNA
(RNAi) led to significant inhibition of DNA synthesis
and increased the percentage of ATRT cells in G2/M
phase [16]. EZH2 might be responsible, at least in part,
for the tumor resistance to radiotherapy [11]. Second, as
an essential downstream target of pRB/E2F pathway,
EZH2 is a critical mediator of E2F function [15]. E2F1
has been observed to be associated with radiosensitivity
and/or chemosensitivity in certain types of tumors
[17-19]. Thus, the pRB/E2F/EZH2 pathway may be one
of the mechanisms involved in tumor response to CRT.
EZH2 high expression has been studied in many solid
tumors [8-13]. But up to now only one report studied
EZH2 expression in 409 colorectal cancer patients but
found no association between EZH2 expression and
prognosis in rectal cancer [26]. In this study we first
showed the significant correlation between EZH2 high
expression and poor prognosis in LARC. The differences
can be explained in two aspects: First, the above study
used the resected tissue while our study used biopsy tis-
sues. Second, the patients in the above study took sur-
gery directly while the patients of this study received
concurrent chemotherapy and radiotherapy followed by
surgery.
In our study, EZH2 over-expression could be a valu-
able prognostic indicator of poor 5-year DFS both in
univariate and multivariate analyses. Refers to 5-year
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predict poor outcome but there is no significant differ-
ence in multivariate analysis. Although the difference
was not significantly, it still revealed a trend the EZH2
over expression showed shorter 5-year OS (p = 0.069).
The similar results were also observed in other solid
tumors [8-13]. In metastatic prostate cancer, EZH2 upreg-
ulated oncogenes and loss of EZH2 inhibited the prolifera-
tion of cancer cells [8,19]. In breast cancer, abnormally
elevated EZH2 levels have been found to be highly cor-
related with tumor cell invasiveness and increased pro-
liferation rates, poor prognosis [27,28]. In ESCC, high
expression of EZH2 was also observed to be an inde-
pendent prognostic factor [11].
The possible mechanisms underlying associations of
high expression of EZH2 and the poor prognosis is very
complexed. The functional consequence of increased
EZH2 expression in cancer tissues includes the silencing
of genes that promote differentiation and restrain prolif-
eration [29]. Currently, EZH2 has been found to func-
tion as a transcriptional repressor that silences an array
of target genes, including more than 200 tumor suppres-
sors [30]. In addition to its role as a transcriptional re-
pressor, several studies have shown that EZH2 may also
function in target gene activation [31-33]. Furthermore,
overexpression of EZH2 is involved in many signaling
pathways, such as the pRB-E2F, PI3K/Akt, estrogen recep-
tor and c-Myc signal transduction pathways [8,15,25,27,34].
These results collectively, suggest that EZH2 high expres-
sion were significantly associated with tumor invasiveness
and poor prognosis, the regulation of protein expression
of EZH2 is quite complicated, and it may be a promising
candidate for anti-cancer treatment.
Conclusion
In this study, we observed, for the first time, EZH2 ex-
pression in LARC could predict the response to nCRT.
EZH2 high expression were significantly associated with
shorter 5-year disease-free survival and 5-year overall
survival in univariate analysis. However, some inherent
limitations of this study might lead to biased results.
First, the current study was a retrospective study and
the number of patients in our study was limited. Second,
the chemotherapeutic regimens were various, which
could affect the tumor response to nCRT [35]. Third, for
tumor heterogeneity, weather a biopsy is representative
of the whole tumor need to be investigated. To further
validate the role of EZH2 in rectal cancer, large consist-
ent cohort studies are needed.
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